Tous Actualités
Suivre
Abonner Genmab A/S

Genmab A/S

T-Cell Lymphoma Patients Achieve Long Lasting Responses With Genmab's HuMax-CD4

Copenhagen, Denmark (ots/PRNewswire)

Genmab A/S (CSE: GEN)
announced today that cutaneous T-cell lymphoma (CTCL) patients in the
HuMax-CD4 Phase II studies achieved long lasting responses, with an
average response duration of more than 6.6 months. This duration of
response data is based on an analysis of responding mycosis fungoides
(MF) patients at all dose levels, 280, 560 and 980 mg.
In addition, median time to disease progression of all 38 MF
patients in the two Phase II studies is more than 5.7 months. Disease
progression is defined as an increase in disease that is more than
25% above the baseline measurement taken when patients entered the
study.
The average duration of response for the high dose patients, who
received either 560 mg or 980 mg, is also more than 6.6 months. In
addition, median time to progression is more than 5.7 months. The
median event time has not yet been reached for the high dose patients
for either measure as more than half the responding patients maintain
their responses and more than half of the high dose patients have not
experienced disease progression. Genmab will continue to follow these
patients.
Six of seven patients who achieved a response at the 560 mg dose
continue to maintain those responses as of the analysis date. These
were early stage patients and generally less heavily pre-treated than
the patients who received the 980 mg dose.
Advanced stage patients, who received either 280 or 980 mg,
obtained a median response duration of 5.3 months and median time to
progression of 4.8 months.
Data for duration of response and time to disease progression have
been calculated as of the end of August, 2004.
These data are being presented at the "Fourth International
Congress on Monoclonal Antibodies in Cancer" in Colorado Springs,
Colorado by Dr. Jan van de Winkel, Genmab's Chief Scientific Officer.
Dr. van de Winkel is also presenting data about the amount of
HuMax-CD4 that was found in patients' bloodstream (serum
concentration) during the study. In these studies, high serum
concentration of HuMax-CD4 appeared to increase the likelihood of a
clinical response.
"I believe the length of the Phase II responses is a positive
sign, especially as the product has been well tolerated in clinical
studies to date," said Lisa N. Drakeman, Ph.D., Chief Executive
Officer of Genmab. "Furthermore, we are encouraged that so many early
stage patients who received the 560 mg dose all seem to be
maintaining their responses. This Phase II data shows the potential
to provide a benefit to patients at a variety of disease stages."
About HuMax-CD4
HuMax-CD4 is a high affinity human antibody that targets the CD4
receptor on T-lymphocytes. Genmab has run two Phase II studies using
HuMax-CD4 to treat CTCL, one in early stage patients and the other
for patients with advanced disease, both of which achieved positive
results. Thirty-eight CTCL patients with MF, the most common form of
CTCL, were treated in these studies. Genmab has a US Orphan Drug
designation for HuMax-CD4 to treat MF patients and is making plans
for a pivotal study with HuMax-CD4 under an FDA Fast Track
Designation for patients who have failed available therapies.
    Conference Call
    Genmab will hold a conference call to discuss the news today Wednesday,
    September 1, 2004 at:
     3:30 pm CET
     2:30 pm BST
     9:30 am EDT
    The conference call will be held in English.
    The dial in numbers are as follows:
     +1-800-500-0177 (in the US) and ask for the Genmab conference call
     +1-719-457-2679 (outside the US) and ask for the Genmab conference call
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops
human antibodies for the treatment of life-threatening and
debilitating diseases. Genmab has numerous products in development to
treat cancer, infectious disease, rheumatoid arthritis and other
inflammatory conditions, and intends to continue assembling a broad
portfolio of new therapeutic products. At present, Genmab has
multiple partnerships to gain access to disease targets and develop
novel human antibodies including agreements with Roche and Amgen. A
broad alliance provides Genmab with access to Medarex, Inc.'s array
of proprietary technologies, including the UltiMAb(TM) platform for
the rapid creation and development of human antibodies to virtually
any disease target. Genmab is headquartered in Copenhagen, Denmark,
and has operations in Utrecht, The Netherlands, and Princeton, New
Jersey in the US. For more information about Genmab, visit
http://www.genmab.com .
Except for the historical information presented herein, matters
discussed in this press release are forward looking statements that
are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results,
performance or achievements expressed or implied by such statements,
e.g. unforeseen exchange rate and interest rate fluctuations, delayed
or unsuccessful development projects.
Statements that are not historical facts, including statements
preceded by, followed by, or that include the words "believes";
"anticipates"; "plans"; "expects"; "estimates"; or similar statements
are forward-looking statements. Genmab is not under an obligation to
up-date statements regarding the future following the publication of
this release; nor to confirm such statements in relation to actual
results, unless this is required by law.
HuMax-CD4(TM) is a trademark of Genmab A/S. UltiMAb(TM) is a
trademark of Medarex, Inc.
Web site: http://www.genmab.com

Contact:

Rachel Gravesen, VP IR&PR of Genmab A/S, +45-33-44-77-34, or mobile,
+45-25-40-30-01, rcg@genmab.com

Plus de actualités: Genmab A/S
Plus de actualités: Genmab A/S